AU2020256847B2 - Method of treating tumours - Google Patents

Method of treating tumours Download PDF

Info

Publication number
AU2020256847B2
AU2020256847B2 AU2020256847A AU2020256847A AU2020256847B2 AU 2020256847 B2 AU2020256847 B2 AU 2020256847B2 AU 2020256847 A AU2020256847 A AU 2020256847A AU 2020256847 A AU2020256847 A AU 2020256847A AU 2020256847 B2 AU2020256847 B2 AU 2020256847B2
Authority
AU
Australia
Prior art keywords
compound
tumour
epoxy
hexahydroxy
tiglien
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020256847A
Other languages
English (en)
Other versions
AU2020256847A1 (en
Inventor
Glen Mathew BOYLE
Jason Kingsley CULLEN
Victoria Anne Gordon
Peter Gordon Parsons
Paul Warren Reddell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QBiotics Pty Ltd
Original Assignee
QBiotics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019901280A external-priority patent/AU2019901280A0/en
Application filed by QBiotics Pty Ltd filed Critical QBiotics Pty Ltd
Publication of AU2020256847A1 publication Critical patent/AU2020256847A1/en
Application granted granted Critical
Publication of AU2020256847B2 publication Critical patent/AU2020256847B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2020256847A 2019-04-12 2020-04-09 Method of treating tumours Active AU2020256847B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019901280A AU2019901280A0 (en) 2019-04-12 Method of Treatment
AU2019901280 2019-04-12
PCT/AU2020/050360 WO2020206504A1 (en) 2019-04-12 2020-04-09 Method of treating tumours

Publications (2)

Publication Number Publication Date
AU2020256847A1 AU2020256847A1 (en) 2021-11-11
AU2020256847B2 true AU2020256847B2 (en) 2025-05-15

Family

ID=72752169

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020256847A Active AU2020256847B2 (en) 2019-04-12 2020-04-09 Method of treating tumours

Country Status (26)

Country Link
US (1) US12226391B2 (cg-RX-API-DMAC7.html)
EP (1) EP3952858B1 (cg-RX-API-DMAC7.html)
JP (2) JP7900152B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210152531A (cg-RX-API-DMAC7.html)
CN (1) CN113924091A (cg-RX-API-DMAC7.html)
AU (1) AU2020256847B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021020253A2 (cg-RX-API-DMAC7.html)
CA (1) CA3136216C (cg-RX-API-DMAC7.html)
DK (1) DK3952858T3 (cg-RX-API-DMAC7.html)
EA (1) EA202192757A1 (cg-RX-API-DMAC7.html)
ES (1) ES3063750T3 (cg-RX-API-DMAC7.html)
FI (1) FI3952858T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20260232T1 (cg-RX-API-DMAC7.html)
IL (1) IL287210B2 (cg-RX-API-DMAC7.html)
LT (1) LT3952858T (cg-RX-API-DMAC7.html)
MX (1) MX2021012449A (cg-RX-API-DMAC7.html)
MY (1) MY208979A (cg-RX-API-DMAC7.html)
PL (1) PL3952858T3 (cg-RX-API-DMAC7.html)
PT (1) PT3952858T (cg-RX-API-DMAC7.html)
RS (1) RS67777B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202110599RA (cg-RX-API-DMAC7.html)
SI (1) SI3952858T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202600066T1 (cg-RX-API-DMAC7.html)
UA (1) UA129840C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020206504A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202108677B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1971588T3 (da) * 2005-12-23 2012-10-22 Qbiotics Ltd Tiglien-3-onderivater
JP7013753B2 (ja) * 2017-09-15 2022-02-01 株式会社三洋物産 遊技機
BR112021024716A2 (pt) 2019-06-19 2022-02-08 QBiotics Pty Ltd Ruptura de biofilme
CN118451065A (zh) * 2021-12-21 2024-08-06 Q生物股份有限公司 结晶中间体
EP4638430A4 (en) * 2022-12-21 2026-07-01 QBiotics Pty Ltd CRYSTALLINE FORMS AND THEIR PRODUCTION PROCESSES

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170559A1 (en) * 2017-03-23 2018-09-27 Qbiotics Limited Combination therapy for the treatment or prevention of tumours

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1971588T3 (da) * 2005-12-23 2012-10-22 Qbiotics Ltd Tiglien-3-onderivater
PT2986615T (pt) 2013-04-18 2019-03-22 Qbiotics Ltd Métodos e composições para a cicatrização de feridas
EP3490547A4 (en) * 2016-07-28 2020-04-01 QBiotics Pty Ltd TREATMENT METHOD

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170559A1 (en) * 2017-03-23 2018-09-27 Qbiotics Limited Combination therapy for the treatment or prevention of tumours

Also Published As

Publication number Publication date
ZA202108677B (en) 2026-03-25
CA3136216A1 (en) 2020-10-15
SI3952858T1 (sl) 2026-04-30
WO2020206504A1 (en) 2020-10-15
AU2020256847A1 (en) 2021-11-11
IL287210B1 (en) 2025-03-01
UA129840C2 (uk) 2025-08-20
IL287210A (en) 2021-12-01
EA202192757A1 (ru) 2022-02-11
CN113924091A (zh) 2022-01-11
MY208979A (en) 2025-06-14
ES3063750T3 (en) 2026-04-20
FI3952858T3 (fi) 2026-02-18
US12226391B2 (en) 2025-02-18
RS67777B1 (sr) 2026-03-31
HRP20260232T1 (hr) 2026-03-27
SMT202600066T1 (it) 2026-03-09
LT3952858T (lt) 2026-04-10
US20220193023A1 (en) 2022-06-23
EP3952858A4 (en) 2022-05-25
SG11202110599RA (en) 2021-10-28
KR20210152531A (ko) 2021-12-15
EP3952858A1 (en) 2022-02-16
PT3952858T (pt) 2026-02-26
CA3136216C (en) 2024-01-16
MX2021012449A (es) 2021-11-12
IL287210B2 (en) 2025-07-01
EP3952858B1 (en) 2025-12-17
JP7900152B2 (ja) 2026-08-04
BR112021020253A2 (pt) 2021-12-07
JP2022528915A (ja) 2022-06-16
DK3952858T3 (da) 2026-02-23
PL3952858T3 (pl) 2026-03-30
JP2025060945A (ja) 2025-04-10

Similar Documents

Publication Publication Date Title
CA3136216C (en) Method of treating tumours
ES2953575T3 (es) Terapia de combinación para el tratamiento o la prevención de tumores
US20250134847A1 (en) Combination therapies
HK40060616A (en) Method of treating tumours
HK40060616B (en) Method of treating tumours
EA044461B1 (ru) Способ лечения опухолей
EA044756B1 (ru) Комбинированная терапия для лечения или предупреждения опухолей
BR112019019748B1 (pt) Usos de um composto de epóxitigliano ou um sal farmaceuticamente aceitável do mesmo, usos de um inibidor do ponto de verificação imunológico e kit

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)